To view this email as a web page, click here.

 
APRIL 2019 ISSUE ALERT
Volume 11, Number 4
Get the full April 2019 digital edition here
Cataract surgery comanagement from the other side, How to educate patients on risks of eyelash enhancements, Pros and cons of private equity firms in practice transitions, and much more available in our digital edition.
Read more
 
Cataract surgery comanagement from the other side
image description here An OD working in a surgical center explains how comanagement with referring ODs occurs at his center. Center doctors educate referring ODs on surgical techniques, IOL options, and treatment as well as consistent patient messaging. Treating ocular surface disease prior to measurements and surgery helps ensure better outcomes.
Learn more
Advertisement
 
How to educate patients on risks of eyelash enhancements
image description here Fake eyelashes are a growing beauty trend among makeup consumers across the globe. But ocular surface complications can arise when proper management and treatment are not practiced. Educate patients on recognizing these signs and how to avoid them.

Learn how
 
Pros and cons of private equity firms in practice transitions
image description here Is the traditional sale of a private practice to a new owner in danger of extinction? Private equity firms offer a new option for ODs looking to transition in or out of practice ownership. Find out the advantages and downsides.

Find out
 
MORE FROM OUR APRIL ISSUE
 
Interest growing in virtual CE
Know the connection between vitamin D and dry eye disease
Case: New protocol for macular hole treatment
5 marketing tips to grow a practice without breaking the bank
How to see 50 patients a day at your practice
4 ways to use eye tracking at your practice
Best practices for comanaging crosslinking patients
Q&A: Sharing space with another OD, ODs on the front line of primary care, and Motorcycle Weekend
 
RESOURCE CENTER
 
Comanagement
 
ADVERTISEMENT
Ad description here
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.